KPTI(KPTI)
KPTI
ANALYST COVERAGE20 analysts
BUY
▲ +79.9%upside to target
L $12.00
Med $14.50consensus
H $28.00PRICE
Prev Close
7.98
Open
7.82
Day Range7.75 – 8.25
7.75
8.25
52W Range3.65 – 10.99
3.65
10.99
60% of range
VOLUME & SIZE
Avg Volume
939.2K
FUNDAMENTALS
P/E Ratio
-0.5x
Not profitable
EPS (TTM)
—
Div Yield
No dividend
Beta
1.55
High vol
TECHNICAL
RSI (14)
46
Bearish momentum
Upcoming Events
EEarnings Report
Tomorrow
May 22
DEx-Dividend
In 90 days
Aug 19
KPTI News
About
karyopharm therapeutics inc. is a clinical-stage pharmaceutical company focused on discovery and development of novel first-in-class drugs directed against nuclear transport targets for the treatment of cancer and other major diseases. for more information, please visit www.karyopharm.com
Industry
Research and Development in Biotechnology (except Nanobiotechnology)
CEO
Michael Kauffman
Website
Reshma RangwalaExecutive Vice President, Chief Medical Officer & Head of Research
Brendan Twohig StrongSenior Vice President of Investor Relations
Richard A. PaulsonPresident, Chief Executive Officer & Director
Sharon ShachamCo-Founder & Chairman of Scientific Advisory Board
James AccumannoChief Compliance Officer
Michael J. ManoExecutive VP, Chief Legal Officer & Secretary
Sohanya ChengExecutive Vice President, Chief Commercial Officer & Head of Business Development
Amama SadiqSenior Vice President of Global Medical & Scientific Affairs
Brian AustadSenior Vice President of Pharmaceutical Sciences
Stuart PoultonExecutive Vice President & Chief Development Officer
Kristin AbateVice President, Chief Accounting Officer & Assistant Treasurer
Lisa DiPaoloExecutive Vice President & Chief Human Resource Officer
Lori A. MacomberExecutive Vice President, Chief Financial Officer & Treasurer